Hello Everyone,
I hope that you have been watching our last few profiles. Several of our more recent ones have gone on to make strong short term double digit moves. Our last one in particular was an exciting one to watch trade during the session.
We have another company that is fresh to our following.
We have never come across this ticker before but after taking a Quick Look at it, we all agree that this is a company tha you need to start your research on right away.
Pull up NRSN right away.
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases.
NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient.
During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense.
To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases.
We are focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases.
Our research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve our goals.
NeuroSense is currently conducting a phase 2b clinical trial using PrimeC in people with ALS. We also commenced research into other possible indications for the platform technology, including Alzheimer’s and Parkinson’s diseases. Additionally, our R&D team is studying the mechanisms of action and relevant biomarkers for these diseases.
NeuroSense’s novel drug, PrimeC, aims to treat ALS by regulating microRNA synthesis, reducing neuroinflammation, and influencing iron accumulation. PrimeC is a novel formulation composed of unique doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, which aim to synergistically inhibit the progression of ALS. The drug mitigates the degeneration and inflammatory response of motor neurons, and has significantly outperformed conventional treatments in a zebrafish model of ALS.
NeuroSense’s preclinical studies showed outstanding results in zebrafish models of ALS. PrimeC was shown to improve motor performance, and recover the morphology of motor neurons, neuromuscular junction structures, and microglial cells. Following these promising results, NeuroSense conducted two clinical trials which have shown that the drug is safe and tolerable, with promising clinical signs. PrimeC has received an orphan drug status from the FDA and EMA, and is currently preparing for a robust Phase 2b/3 clinical trial.
Due to the many shared pathways between neurodegenerative diseases, the hypothesis is that a disease-modifying drug for one, can lay the foundations for effective drugs for other neurodegenerative diseases. Therefore, we are working to develop a drug for Alzheimer’s based on the foundations of PrimeC. We have initiated the pre-clinical stage, testing CogniC in in-vitro models representing Alzheimer’s disease pathologies, and now initiating a phase 2 double blind placebo controlled study with 20 AD patients.
There are many shared pathways between Parkinson’s disease and ALS, such as neuroinflammation, protein aggregation, mitophagy, excitotoxicity, oxidative stress, iron accumulation, and dysregulation of miRNAs. Therefore, we are working to develop a drug for Parkinson’s based on the foundations of our drug, PrimeC, for ALS. We have initiated the pre-clinical stage, testing StabiliC in in-vivo models of Parkinson’s, assessing morphological and functional effects, exploring potential co-development with collaborators that have core focus in Parkinsons.
READ THE FULL REPORT HERE: https://www.insiderfinancial.com/profile/nrsn
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, SHORE THING MEDIA, LLC FOR A ONE DAY NRSN PROFILE.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.
Insider Financial
1337 Mass. AveBox 211
Arlington, MA 02476
No comments:
Post a Comment